Capecitabine, Bevacizumab, and Radiation Therapy Followed By Gemcitabine and Bevacizumab in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By Surgery

Inclusion Criteria: Histologically confirmed adenocarcinoma of the pancreas Locally advanced disease Unresectable disease All malignant disease must be encompassable within a single irradiation field Radiographically assessable disease Patients with biliary or gastroduodenal obstruction are eligible provided drainage or surgical bypass was performed prior to initiation of study treatment No evidence of gastric outlet obstruction No evidence of duodenal invasion on CT scan No evidence of metastatic disease in the major viscera No peritoneal seeding or ascites Performance status - Zubrod 0-1 Granulocyte count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 No evidence of bleeding diathesis ALT < 3 times upper limit of normal Bilirubin < 2.0 mg/dL INR ≤ 1.5 No evidence of coagulopathy Creatinine clearance > 50 mL/min Urine protein < 1,000 mg by 24-hour urine collection (for patients with proteinuria ≥ 1+ by dipstick or urinalysis OR urine protein:creatinine ratio ≥ 1.0) No myocardial infarction within the past 6 months No unstable angina within the past 6 months No arterial thromboembolic events within the past 6 months, including any of the following: Transient ischemic attack Cerebrovascular accident Clinically significant peripheral artery disease No unstable symptomatic arrhythmia requiring medication (e.g., chronic atrial arrhythmia [i.e., atrial fibrillation or paroxysmal supraventricular tachycardia]) Patients with an atrial arrhythmia are eligible provided the condition is well controlled on stable medication No New York Heart Association class II-IV congestive heart failure No history of arteriovenous malformation No history of aneurysm No uncontrolled hypertension (i.e., blood pressure > 160/90 mm Hg with medication) No other clinically significant cardiac disease No AIDS No significant infection No known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies Not pregnant No nursing during and for ≥ 3-4 months after completion of study treatment Negative pregnancy test Fertile patients must use effective contraception during and for ≥ 3-4 months after completion of study treatment No history of gastrointestinal fistula or perforation No other malignancy within the past two years except nonmelanoma skin cancer or carcinoma in situ of the cervix, uterus, or bladder No significant traumatic injury within the past 4 weeks No serious nonhealing wound or ulcer No current healing fracture No known or suspected dihydropyrimidine dehydrogenase deficiency No other medical condition that would preclude study participation No concurrent interleukin-11 No prior chemotherapy for pancreatic cancer More than 2 years since prior chemotherapy for another malignancy No prior radiotherapy to the planned irradiation field No concurrent intensity modulated radiotherapy No other concurrent radiotherapy See Disease Characteristics More than 4 weeks since prior major surgical procedure or open biopsy More than 1 week since prior fine needle aspiration or core biopsy No prior organ transplantation No concurrent major surgical procedure More than 30 days since prior and no concurrent cimetidine Concurrent ranitidine or a drug from another anti-ulcer class allowed More than 4 weeks since prior and no concurrent sorivudine or brivudine No concurrent warfarin during chemoradiotherapy Concurrent warfarin allowed beginning 2 weeks after completion of chemoradiotherapy Concurrent low molecular weight heparin allowed (at any time during study participation) No other concurrent investigational agents No other concurrent cytotoxic agents